{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118395","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.563547+00:00","generated_at":"2026-06-08T02:24:10.212425+00:00","sec_items":["1.01","1.02","2.03","3.02","3.03","5.01","5.02","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Mallinckrodt emerges from Chapter 11; old equity cancelled, $1.65B new debt issued","bullets":["On Nov 14, 2023, Mallinckrodt emerged from US Chapter 11 and Irish examinership under a prepackaged plan.","All existing ordinary shares were cancelled; 19,696,335 new common shares issued: 92.3% to first-lien creditors, 7.7% to second-lien noteholders.","Issued $871.4M in Takeback Term Loans (SOFR+7.5%/9.5%) and $778.6M in 14.75% Takeback Notes due 2028.","Issued 1,036,649 CVRs exercisable until Nov 2027; entitles holder to cash or equity based on market price minus $99.36.","Board resigned except CEO; David Stetson and Jon Zinman appointed as new directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118395","json":"https://secwatch.observer/filing/0001104659-23-118395.json","markdown":"https://secwatch.observer/filing/0001104659-23-118395.md","text":"https://secwatch.observer/filing/0001104659-23-118395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/tm2330452d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:24:10.212425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1387d89fe9","claim":"Paul M. Bisaro resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"197444da79","claim":"Susan Silbermann resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"21ff5e5faa","claim":"James R. Sulat resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4e9046a056","claim":"Sigurdur Olafsson resigned as President and Chief Executive Officer at Keenova Therapeutics plc.","evidence_excerpt":"Mr. Olafsson provided written notice of his intention to resign as an employee effective on the 75 th day following the Effective Date (the “ Post-Emergence Resignation Date ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a3023553cf","claim":"Jon Zinman was appointed as Director at Keenova Therapeutics plc.","evidence_excerpt":"On the Effective Date and immediately following the Director Resignations, the following individuals were appointed directors of Mallinckrodt: David Stetson and Jon Zinman (collectively, the “ New Directors ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a69769e663","claim":"David Stetson was appointed as Director at Keenova Therapeutics plc.","evidence_excerpt":"On the Effective Date and immediately following the Director Resignations, the following individuals were appointed directors of Mallinckrodt: David Stetson and Jon Zinman (collectively, the “ New Directors ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"aac450606b","claim":"Karen Ling resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"adec099ed5","claim":"Riad El-Dada resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bc23704641","claim":"Dr. Woodrow Myers resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d1dcf81c44","claim":"Neal P. Goldman resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"da244aa486","claim":"Daniel Celentano resigned as Director at Keenova Therapeutics plc.","evidence_excerpt":"All of the directors of the board of directors of Mallinckrodt (the “ Board ”) then serving, other than Sigurdur Olafsson, our President and Chief Executive Officer, resigned effective as of the Effective Date from their roles as directors of Mallinckrodt (and any committees of the Board thereof) (collectively, the “ Director Resignations ”), including: Paul M. Bisaro, Daniel Celentano, Riad El-Dada, Neal P. Goldman, Karen Ling, Dr. Woodrow Myers, Susan Silbermann and James R. Sulat.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6a723ded2683362899723ef6a928011cc2bc4633","claim":"Keenova Therapeutics plc: Adopted New Articles of Association replacing Prior Articles of Association, changing authorized share capital, board composition, preemptive rights, and other governance provisions.","evidence_excerpt":"Effective as of the Effective Date, and pursuant to the Scheme of Arrangement, the new memorandum and articles of association (together, the \" New Articles of Association \") were adopted, which replaced and superseded the prior memorandum and articles of association (together, the \" Prior Articles of Association \"), respectively.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"1f7a867ab40895e4f2882fc5fc89c2e79801afb8","claim":"Keenova Therapeutics plc entered into Registration Rights Agreement with certain owners of New Common Equity valued at Provides piggyback registration rights and demand registration rights for Company Shareholders ownin.","evidence_excerpt":"On the Effective Date and pursuant to the Plan, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with certain owners of New Common Equity","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"certain owners of New Common Equity"},{"label":"Value","value":"Provides piggyback registration rights and demand registration rights for Company Shareholders ownin"}],"fact_type":"material_agreement"},{"claim_id":"79172672fd27062a8c2bce9e8661450a9c0bc53a","claim":"Keenova Therapeutics plc entered into Contingent Value Right Agreement with Trust valued at Issued 1,036,649 CVRs entitling Trust to receive cash equal to Market Price of one new ordinary shar.","evidence_excerpt":"On the Effective Date and pursuant to the Plan, the Company entered into a contingent value right agreement (the “ CVR Agreement ”) with the Trust.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Trust"},{"label":"Value","value":"Issued 1,036,649 CVRs entitling Trust to receive cash equal to Market Price of one new ordinary shar"}],"fact_type":"material_agreement"},{"claim_id":"b0166f556839dc38b9e542df1056dd8ccfcaf4e1","claim":"Keenova Therapeutics plc entered into Information Rights Deed with Information Rights Holders valued at Company to provide Information Rights Holders with quarterly unaudited financial statements within 6.","evidence_excerpt":"On the Effective Date and pursuant to the Plan, the Company entered into a deed poll relating to the information rights members of the Company (the “ Information Rights Deed ”) for the benefit of each Company Shareholder that","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Information Rights Holders"},{"label":"Value","value":"Company to provide Information Rights Holders with quarterly unaudited financial statements within 6"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}